Early Is Not Upstream: Interpreting Biomarker Timing in Alzheimer’s Disease

An independent systematic-review project shows why early biomarker change does not establish upstream causality—and how a focused Evidence Brief keeps the limits visible.

A biomarker can change years before symptoms and still fail to sit upstream of another biomarker in the disease process.

That distinction matters whenever evidence is converted into a clinical claim, an educational slide, a product rationale or a research decision.

The difference between “early” and “upstream”

Early is a temporal description relative to an event such as symptom onset, diagnosis or a study-defined threshold. Upstream is a stronger claim: it implies that one process precedes another in the relevant biological sequence and may contribute to what follows.

Those statements are not interchangeable. A marker may become abnormal during a presymptomatic period while changing after phosphorylated tau. It may also correlate with disease stage without establishing causal precedence.

What the independent review project examined

An independently conducted systematic-review project asked whether astrocytic or lipid-handling biomarkers consistently become abnormal before phosphorylated tau in genetically at-risk Alzheimer’s disease populations.

The protocol was registered on OSF and versioned on Zenodo. The project is not presented here as a published article or peer-reviewed guideline.

The strict evidence base included 25 reports representing 19 studies. Nine timing studies yielded 14 dependent target–tau timing rows. Across those nine studies, the eligible target marker was earlier in one study, near-contemporaneous in two and p-tau was earlier in six.

These are study-level direction counts, not a pooled effect estimate.

Why a pooled number was not the answer

A meta-analysis was not performed because the assays, matrices, thresholds and trajectory procedures differed; several rows and cohorts were dependent; and paired change-point uncertainty was absent.

Pooling under those conditions would have created a precise-looking number without resolving the underlying comparability problem.

That decision is itself a useful result. Evidence synthesis should not force a numerical answer when the available data cannot support one.

The practical implication

The reviewed evidence supports continued biomarker development, but it does not justify describing an astrocytic or lipid-handling marker as a validated upstream predecessor of p-tau.

For scientific and educational content, four questions should come before an upstream claim:

  1. Earlier than what reference point?
  2. Was the comparator measured in the same participants?
  3. Were thresholds, assays and sampling schedules comparable?
  4. Does the study establish temporal ordering, incremental prediction or only association?

Keeping those questions visible protects the distinction between observation and inference.

What a focused Evidence Brief is for

A Rapid Medical Evidence Brief addresses one focused clinical, scientific or strategic question. It provides a scoped search, structured evidence table, concise synthesis, limitations and decision-relevant implications.

The fixed fee is US$1,200. This is not a full systematic review, publication guarantee or regulatory sign-off.

Send one focused question, the intended audience and the decision deadline. Receive a written scope, delivery date and fixed fee within one business day.

Request a scope:
https://www.malheirosresearch.com/request-scope/?utm_source=ghost&utm_medium=newsletter&utm_campaign=alzheimer_biomarker_timing_sep2026&utm_content=rapid_evidence_brief

Explore the labelled demonstration sample:
https://www.malheirosresearch.com/evidence-brief-sample/?utm_source=ghost&utm_medium=newsletter&utm_campaign=alzheimer_biomarker_timing_sep2026&utm_content=evidence_brief_sample

References and scientific status

Protocol registration: OSF, DOI 10.17605/OSF.IO/54GEF
Protocol version 4.1: Zenodo, DOI 10.5281/zenodo.22111898
Public demonstration: DEMONSTRATION SAMPLE - NOT CLIENT WORK

The source project is an independent systematic-review project. It is not described here as a published journal article or clinical guideline.